{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:21:12Z","timestamp":1774340472724,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Antithrombotic agents have a role in coronavirus disease 2019 (COVID-19) treatment, but the pandemic disrupted medication supply. This study examined changes in the volume of oral and parenteral anticoagulant and antiplatelet medications at US hospitals during the pandemic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>IQVIA National Sales Perspective (NSP) data was used to determine the monthly volume of anticoagulants and antiplatelets purchased at US hospitals between January 2018 and February 2021. Mean monthly medication volumes, reported as extended units (EUs), and year-over-year changes in medication volume were determined. A single-group interrupted time series analysis was used to evaluate changes in the rate of growth of monthly medication volumes before (January 2019-February 2020) and during (March 2020-February 2021) the COVID-19 pandemic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, there was a 43.4% decline in the total volume of anticoagulants and antiplatelets at US hospitals in March 2020, driven by a decrease in heparin volume. Mean monthly volumes decreased significantly (P &amp;lt; 0.05) for parenteral anticoagulants (\u2013106,691,340 EU [95% CI, \u2013200,033,910 to \u201313,348,780]), oral anticoagulants (\u2013354,800 EU [95% CI, \u2013612,180 to \u201397,420]), and parenteral antiplatelets (\u2013391,880 EU [95% CI, \u2013535,420 to \u2013248,330]). During the pandemic, the monthly volume of oral anticoagulants, parenteral anticoagulants, and parenteral antiplatelets grew significantly more than in the prepandemic period. This growth was primarily seen in volumes of apixaban, argatroban, enoxaparin, heparin, eptifibatide, and tirofiban. Apixaban and heparin volumes continued a prepandemic uptrend, while argatroban and eptifibatide volumes reversed trend.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Rapid changes in anticoagulant and antiplatelet volume at US hospitals during the COVID-19 pandemic highlight the need for institutional protocols to manage fluctuating medication volume demands.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac381","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T11:42:02Z","timestamp":1672054922000},"page":"692-698","source":"Crossref","is-referenced-by-count":5,"title":["Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021)"],"prefix":"10.1093","volume":"80","author":[{"given":"Paul J","family":"Wong","sequence":"first","affiliation":[{"name":"University of Southern California School of Pharmacy , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A","family":"Mosley","sequence":"additional","affiliation":[{"name":"University of Southern California School of Pharmacy , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien M H","family":"Ng","sequence":"additional","affiliation":[{"name":"University of Southern California School of Pharmacy , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Shooshtari","sequence":"additional","affiliation":[{"name":"University of Southern California School of Pharmacy , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health , Baltimore, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima M","family":"Qato","sequence":"additional","affiliation":[{"name":"University of Southern California School of Pharmacy , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2023060913384258400_CIT0001","author":"Centers for Disease Control and Prevention"},{"key":"2023060913384258400_CIT0002","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ahj.2020.06.009","article-title":"COVID-19 and the cardiovascular system: a review of current data, summary of best practices, outline of controversies, and illustrative case reports","volume":"226","author":"Prasad","year":"2020","journal-title":"Am Heart J"},{"issue":"9","key":"2023060913384258400_CIT0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2023060913384258400_CIT0004","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2023060913384258400_CIT0005","author":"National Institutes of Health","year":"2022"},{"key":"2023060913384258400_CIT0006","author":"US Food and Drug Administration"},{"issue":"1","key":"2023060913384258400_CIT0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2020.6016","article-title":"Ensuring access to medications in the US during the COVID-19 pandemic","volume":"324","author":"Alexander","year":"2020","journal-title":"JAMA"},{"key":"2023060913384258400_CIT0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2951684","article-title":"Testing the autocorrelation structure of disturbances in ordinary least squares and instrumental variables regressions","volume":"60","author":"Cumby","year":"1992","journal-title":"Econometrica"},{"key":"2023060913384258400_CIT0009","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single- and multiple-group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"Stata J"},{"key":"2023060913384258400_CIT0010","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or avoidance of medical care because of COVID-19\u2013related concerns \u2014 United States, June 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2023060913384258400_CIT0011","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1161\/STROKEAHA.120.033630","article-title":"Acute coronary syndrome and ischemic stroke discharges in the United States during the COVID-19 pandemic","volume":"52","author":"de Havenon","year":"2021","journal-title":"Stroke"},{"issue":"6","key":"2023060913384258400_CIT0012","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/rth2.12414","article-title":"Anticoagulation practice patterns in COVID-19: a global survey","volume":"4","author":"Rosovsky","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2023060913384258400_CIT0013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.15585\/mmwr.mm7104e4","article-title":"Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods \u2013 United States, December 2020-January 2022","volume":"71","author":"Iuliano","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10320","key":"2023060913384258400_CIT0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Collaborative Group","year":"2022","journal-title":"Lancet"},{"issue":"10223","key":"2023060913384258400_CIT0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(19)33135-6","article-title":"Running thin: implications of a heparin shortage","volume":"395","author":"McCarthy","year":"2020","journal-title":"Lancet"},{"issue":"10319","key":"2023060913384258400_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac381\/48614942\/zxac381.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/11\/692\/50521978\/zxac381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/11\/692\/50521978\/zxac381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:35:37Z","timestamp":1686321337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/11\/692\/6960873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,12,26]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac381","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,12,26]]}}}